Literature DB >> 18499121

Evaluation of a multiplex flow cytometric immunoassay to detect PR3- and MPO-ANCA in active and treated vasculitis, and in inflammatory bowel disease (IBD).

Michelle Trevisin1, Wendy Pollock, Wayne Dimech, Judy Savige.   

Abstract

This study compared the performance of a flow cytometric immunoassay for antineutrophil cytoplasmic antibodies (ANCA) directed against proteinase 3 (PR3) and myeloperoxidase (MPO), with indirect immunofluorescence (IIF) and ELISAs from 12 different manufacturers. Sera were from patients with active (n=55) or treated (n=68) small vessel vasculitis, or inflammatory bowel disease (IBD, n=22). The immunoassay specificity was 88% compared with 96% for IIF and 94% (median, range 91-96%) for both ELISAs. Its sensitivity in treated disease was 82% compared with 84% for IIF and 69% (median, range 57-82%) for the ELISAs. The immunoassay's specificity was 88% which was the same as the median for both ELISAs (range 84-95%). The PR3- and MPO-ANCA immunoassay was almost as sensitive as IIF, and more sensitive than, but just as specific as, most ELISAs, in detecting ANCA in active and treated vasculitis. A major advantage of this assay is its ability to be further modified to simultaneously screen for a panel of autoantibodies relevant to vasculitis.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18499121     DOI: 10.1016/j.jim.2008.03.012

Source DB:  PubMed          Journal:  J Immunol Methods        ISSN: 0022-1759            Impact factor:   2.303


  9 in total

1.  Myeloperoxidase-antineutrophil Cytoplasmic Antibodies (MPO-ANCA) and Proteinase 3-ANCA without Immunofluorescent ANCA Found by Routine Clinical Testing.

Authors:  Deepak A Rao; Kevin Wei; Joseph F Merola; William R O'Brien; Samuel U Takvorian; Paul F Dellaripa; Peter H Schur
Journal:  J Rheumatol       Date:  2015-04-01       Impact factor: 4.666

Review 2.  Laboratory investigation in the diagnosis of vasculitis.

Authors:  Luis Felipe Flores-Suárez
Journal:  Curr Rheumatol Rep       Date:  2009-12       Impact factor: 4.592

3.  Discrepancies between two immunoassays for the determination of MPO and PR3 autoantibodies.

Authors:  Qian Sun; Boris Calderon; Zhen Zhao
Journal:  Clin Chim Acta       Date:  2017-05-08       Impact factor: 3.786

4.  Presence of anti-proteinase 3 antineutrophil cytoplasmic antibodies (anti-PR3 ANCA) as serologic markers in inflammatory bowel disease.

Authors:  Maria Teresa Arias-Loste; Geovana Bonilla; Irene Moraleja; Michael Mahler; Miguel Angel Mieses; Beatriz Castro; Montserrat Rivero; Javier Crespo; Marcos López-Hoyos
Journal:  Clin Rev Allergy Immunol       Date:  2013-08       Impact factor: 8.667

Review 5.  [Paradigm shift in ANCA diagnostics : New international consensus recommendations].

Authors:  E Csernok; N Kempiners; B Hellmich
Journal:  Z Rheumatol       Date:  2017-03       Impact factor: 1.372

Review 6.  Current and emerging techniques for ANCA detection in vasculitis.

Authors:  Elena Csernok; Frank Moosig
Journal:  Nat Rev Rheumatol       Date:  2014-06-03       Impact factor: 20.543

Review 7.  Twenty-eight years with antineutrophil cytoplasmic antibodies (ANCA): how to test for ANCA - evidence-based immunology?

Authors:  Elena Csernok; Julia U Holle
Journal:  Auto Immun Highlights       Date:  2010-07-10

8.  PR3-ANCA: a promising biomarker in primary sclerosing cholangitis (PSC).

Authors:  Laura M Stinton; Chelsea Bentow; Michael Mahler; Gary L Norman; Bertus Eksteen; Andrew L Mason; Gilaad G Kaplan; Bjorn Lindkvist; Gideon M Hirschfield; Piotr Milkiewicz; Angela Cheung; Harry L A Janssen; Marvin J Fritzler
Journal:  PLoS One       Date:  2014-11-14       Impact factor: 3.240

Review 9.  Novel clinical and diagnostic aspects of antineutrophil cytoplasmic antibodies.

Authors:  Johannes Schulte-Pelkum; Antonella Radice; Gary L Norman; Marcos Lόpez Hoyos; Gabriella Lakos; Carol Buchner; Lucile Musset; Makoto Miyara; Laura Stinton; Michael Mahler
Journal:  J Immunol Res       Date:  2014-06-05       Impact factor: 4.818

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.